Rivus Pharmaceuticals, Inc., is dedicated to transforming the treatment of cardio-metabolic disease by advancing a new class of oral, once daily, small molecule therapeutics called Controlled Metabolic Accelerators (CMAs). Rivus’ CMAs are designed to improve cellular metabolism and treat the underlying cause of highly prevalent metabolic and cardiovascular diseases including type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), as well as cardiovascular diseases such as heart failure with reduced ejection fraction (HFpEF). For more information please visit https://www.rivuspharma.com/
Member count: 11-50
Total raised: $167M
Founded date: 2019
Investors 1
| Date | Name | Website |
| 02.10.2022 | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 22.09.2022 | Series B | $132M | - | finsmes.co... |
| 22.07.2021 | Series A | $35M | - | prnewswire... |
Mentions in press and media 4
| Date | Title | Description | Category | Author | Source |
| 22.09.2022 | Rivus Phar... | Rivus Pharmaceuticals Inc., a ... | USA | - | finsmes.co... |
| 22.07.2021 | Rivus Phar... | Rivus Pharmaceuticals, Inc., a... | USA | - | finsmes.co... |
| 20.07.2021 | Rivus Phar... | CHARLOTTESVILLE, Va., July 2... | - | - | prnewswire... |
| - | Rivus Phar... | “Rivus will improve cardio-met... | - | - | fastfounde... |